REPL insider trading
NasdaqGS HealthcareReplimune Group, Inc.: insider trade history from SEC Form 4 filings.
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Company website: www.replimune.com
REPL insider activity at a glance
FilingIQ tracks 378 insider transactions for REPL in filings since Jul 25, 2018. The most recent transaction is dated Aug 20, 2026.
Across the full history, 7 open-market purchases
and 270 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on REPL insider trades is 56.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest REPL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding REPL
Frequently asked
- How many insider trades does FilingIQ track for REPL?
- FilingIQ tracks 378 Form 4 insider transactions for REPL (Replimune Group, Inc.), covering filings from Jul 25, 2018 onwards. 6 of those are dated within the last 90 days.
- Are REPL insiders net buyers or net sellers?
- Across the full Form 4 history for REPL, 7 transactions (2%) were open-market purchases and 270 (71%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does REPL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is REPL in?
- Replimune Group, Inc. (REPL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $701.87M.
Methodology & sources
Every REPL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.